Oncology Dominates As China Approves Record 48 New Drugs In 2018
Executive Summary
Despite multiple adverse factors including a leadership shakeup and the departure of its top regulator, the China FDA seemed determined to refresh itself after a name change and to speed up new drugs to market.
You may also be interested in...
China's Innovent Biologics Emerges As Immuno-Oncology Competitor With Sintilimab Approval
Medicines regulators have cleared Innovent Biologics's anti-PD-1 therapy, sintilimab, for classical Hodgkin's lymphoma in China, where late-stage studies as a first-line therapy for advanced esopheageal cancer have also just started.
First Approval For AZ's Roxadustat With China Green Light
China is the first country to give the green light to roxadustat, AstraZeneca and FibroGen's first-in-class oral inhibitor of HIF-PHI, which could become standard of care to treat anemia in chronic kidney disease patients.
Unbearable Lightness? China Levies Record $1.3bn Fine Amid Vaccine Scandal
Record-breaking fine slapped on scandal-hit domestic vaccine maker in China has some wondering if the tide of opinion may be turning against private companies.